Aspirin/clopidogrel - Sanofi

Drug Profile

Aspirin/clopidogrel - Sanofi

Alternative Names: Clopidogrel/aspirin - Sanofi; ComPlavin; DuoCover; DuoPlavin

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antiplatelets; Antipyretics; Pyridines; Salicylic acids; Small molecules; Thienopyridines
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute coronary syndromes

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute coronary syndromes(In volunteers) in South Korea (PO, Tablet)
  • 31 Mar 2015 Launched for Acute coronary syndromes in Greece, Italy, France, Portugal, Poland, Czech Republic, Croatia, Slovenia, Lithuania, Switzerland, Georgia, Russia and Ukraine (PO) before March 2015
  • 31 May 2011 Sanofi-aventis is now called Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top